What is the most recent FDA action against Major Pharmaceuticals?

The most recent FDA event Argus HQ has on file for Major Pharmaceuticals is dated 2026-07-29, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Does Argus HQ track new FDA actions for Major Pharmaceuticals automatically?

Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to Major Pharmaceuticals is observed, this page's event count and history update automatically.

How many FDA actions does Argus HQ track for Major Pharmaceuticals?

12 total: 0 warning letters, 12 recalls, 0 approval records, and 0 Form 483 inspection citations.

What is the most recent FDA action on file for Major Pharmaceuticals?

July 29, 2026. Argus HQ ingests new FDA enforcement records daily.

Major Pharmaceuticals's Complete FDA Record

FDA action counts

Total FDA actions	12
Warning letters	0
Recalls	12
Approval records	0
Form 483 inspection citations	0
Most recent action	July 29, 2026

Key takeaway: Argus HQ has recorded 12 FDA events for Major Pharmaceuticals: 0 warning letters, 12 recalls, 0 approvals, and 0 inspection 483 observations. These events span from 2026-07-29 to 2026-07-29. The most severe rating Argus HQ has assigned across this history is "high". Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed.

Risk pattern analysis

Argus HQ analysis — not an FDA finding

This section is Argus HQ analysis, not an FDA finding. Major Pharmaceuticals has 12 separate FDA recalls on file, more than a single isolated recall event. A pattern across multiple FDA touchpoints does not by itself establish that any specific product currently poses a risk; it reflects only the frequency of FDA engagement with this company as recorded in Argus HQ's database. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures. This page reflects only the FDA event types Argus HQ currently tracks -- FDA Warning Letters, recalls, drug and biologic approvals, and Form 483 inspection observations -- and will update automatically as new FDA records are observed. Argus HQ does not independently verify FDA's underlying findings; this page summarizes what FDA has published and links back to the original FDA source for each event. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.

Enforcement history

On 2026-07-29, Argus HQ recorded an FDA recall for Major Pharmaceuticals, rated "high" severity in Argus HQ's classification: Major Pharmaceuticals — Class II recall: Levothyroxine Sodium Tablets, USP, 50 mcg (0.050 mg), 100 Tablets (10 x 10 unit…. On 2026-07-29, Argus HQ recorded an FDA recall for Major Pharmaceuticals, rated "high" severity in Argus HQ's classification: Major Pharmaceuticals — Class II recall: Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 100 Tablets (10 x 10 unit…. On 2026-07-29, Argus HQ recorded an FDA recall for Major Pharmaceuticals, rated "high" severity in Argus HQ's classification: Major Pharmaceuticals — Class II recall: Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 100 Tablets (10 x 10 unit…. On 2026-07-29, Argus HQ recorded an FDA recall for Major Pharmaceuticals, rated "high" severity in Argus HQ's classification: Major Pharmaceuticals — Class II recall: Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 10 Tablets (10 x 1) unit d…. On 2026-07-29, Argus HQ recorded an FDA recall for Major Pharmaceuticals, rated "high" severity in Argus HQ's classification: Major Pharmaceuticals — Class II recall: Levothyroxine Sodium Tablets, USP, 50 mcg (0.050 mg), 10 Tablets (10 x 1) unit d…. On 2026-07-29, Argus HQ recorded an FDA recall for Major Pharmaceuticals, rated "high" severity in Argus HQ's classification: Major Pharmaceuticals — Class II recall: Levothyroxine Sodium Tablets, USP, 150 mcg (0.0150 mg), 100 Tablets (10 x 10 uni…. On 2026-07-29, Argus HQ recorded an FDA recall for Major Pharmaceuticals, rated "high" severity in Argus HQ's classification: Major Pharmaceuticals — Class II recall: Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 10 Tablets (10 x 1) unit d…. On 2026-07-29, Argus HQ recorded an FDA recall for Major Pharmaceuticals, rated "high" severity in Argus HQ's classification: Major Pharmaceuticals — Class II recall: Levothyroxine Sodium Tablets, USP, 125 mcg (0.0125 mg), 100 Tablets (10 x 10 uni…. On 2026-07-29, Argus HQ recorded an FDA recall for Major Pharmaceuticals, rated "high" severity in Argus HQ's classification: Major Pharmaceuticals — Class II recall: Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 100 Tablets (10 x 10 unit…. On 2026-07-29, Argus HQ recorded an FDA recall for Major Pharmaceuticals, rated "high" severity in Argus HQ's classification: Major Pharmaceuticals — Class II recall: Levothyroxine Sodium Tablets, USP, 112 mcg (0.0112 mg), 100 Tablets (10 x 10 uni…. On 2026-07-29, Argus HQ recorded an FDA recall for Major Pharmaceuticals, rated "high" severity in Argus HQ's classification: Major Pharmaceuticals — Class II recall: Levothyroxine Sodium Tablets, USP, 150 mcg (0.0150 mg), 10 Tablets (10 x 1) unit…. On 2026-07-29, Argus HQ recorded an FDA recall for Major Pharmaceuticals, rated "high" severity in Argus HQ's classification: Major Pharmaceuticals — Class II recall: Levothyroxine Sodium Tablets, USP, 125 mcg (0.0125 mg), 10 Tablets (10 x 1) unit….

Frequently asked questions

What is the most recent FDA action against Major Pharmaceuticals?: The most recent FDA event Argus HQ has on file for Major Pharmaceuticals is dated 2026-07-29, with a severity rating of "high" in Argus HQ's classification. Argus HQ ingests these records directly from FDA's own public enforcement and approval databases rather than from company disclosures.
Does Argus HQ track new FDA actions for Major Pharmaceuticals automatically?: Yes. Argus HQ ingests FDA sources daily, including FDA warning letters, recalls, drug and biologic approvals, and Form 483 inspection observations. When a new FDA action linked to Major Pharmaceuticals is observed, this page's event count and history update automatically.
How many FDA actions does Argus HQ track for Major Pharmaceuticals?: 12 total: 0 warning letters, 12 recalls, 0 approval records, and 0 Form 483 inspection citations.
What is the most recent FDA action on file for Major Pharmaceuticals?: July 29, 2026. Argus HQ ingests new FDA enforcement records daily.

Every FDA action tied to this company, the week it happens.

Free weekly briefing. Real-time alerts on paid plans.

Compare with

Two different companies merged onto this page by mistake? Or a name variant missing? Tell us — corrections@argushq.ai

Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder

Verified from FDA.gov · Last updated: Jul 29, 2026

Cite this record

Reusing this data in reporting or research? Here’s a ready-made citation.

APA

Argus HQ Research (2026). Major Pharmaceuticals's Complete FDA Record. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/company/major-pharmaceuticals

MLA

"Major Pharmaceuticals's Complete FDA Record." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/company/major-pharmaceuticals.

Chicago

Argus HQ Research. "Major Pharmaceuticals's Complete FDA Record." Digital Empire Holdings LLC. Accessed August 4, 2026. https://argushq.ai/company/major-pharmaceuticals.

BibTeX

@misc{argushq_argushq_ai_company_major_pharmaceuticals_2026,
  title = {Major Pharmaceuticals's Complete FDA Record},
  author = {{Argus HQ Research}},
  year = {2026},
  publisher = {Digital Empire Holdings LLC},
  url = {https://argushq.ai/company/major-pharmaceuticals},
  note = {Accessed: August 4, 2026}
}

Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗